Sarepta Therapeutics Inc (SRPT) Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC lowered its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 16.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 7,320 shares of the biotechnology company’s stock after selling 1,420 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Sarepta Therapeutics were worth $1,182,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SRPT. First Quadrant L P CA purchased a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $130,000. Rockefeller Capital Management L.P. purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $185,000. Keybank National Association OH purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $206,000. Finally, Kovack Advisors Inc. purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $217,000. Institutional investors and hedge funds own 89.84% of the company’s stock.

A number of research analysts have recently commented on the company. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Credit Suisse Group assumed coverage on Sarepta Therapeutics in a research note on Thursday, September 6th. They issued an “outperform” rating and a $178.00 target price for the company. Citigroup raised their target price on Sarepta Therapeutics from $174.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Sanford C. Bernstein assumed coverage on Sarepta Therapeutics in a research note on Friday, October 12th. They issued an “outperform” rating and a $170.00 target price for the company. Three research analysts have rated the stock with a hold rating, twenty-four have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $169.19.

In related news, CFO Sandesh Mahatme sold 107,524 shares of the firm’s stock in a transaction that occurred on Wednesday, October 24th. The stock was sold at an average price of $127.74, for a total transaction of $13,735,115.76. Following the completion of the transaction, the chief financial officer now owns 48,381 shares of the company’s stock, valued at approximately $6,180,188.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $140.50, for a total value of $936,713.50. Following the transaction, the director now directly owns 126,534 shares of the company’s stock, valued at approximately $17,778,027. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.

SRPT stock opened at $125.46 on Friday. Sarepta Therapeutics Inc has a twelve month low of $50.68 and a twelve month high of $176.50. The company has a quick ratio of 7.84, a current ratio of 8.85 and a debt-to-equity ratio of 0.65.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.29). Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. The company had revenue of $78.49 million for the quarter, compared to the consensus estimate of $78.84 million. On average, equities research analysts forecast that Sarepta Therapeutics Inc will post -4.38 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sarepta Therapeutics Inc (SRPT) Shares Sold by Lisanti Capital Growth LLC” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/sarepta-therapeutics-inc-srpt-shares-sold-by-lisanti-capital-growth-llc.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Featured Article: Initial Public Offering (IPO)

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply